anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an artificial synthetic adjuvant for avian influenza intranasal immunization, which belong to the technical field of biology and is specially used for applying avian influenza inactivated virus intranasal immunization. The function of CpG oligodeoxynucleotide (ODN) is closely related to the sequence and structural features. A plurality of CpG-ODN sequences are designed according to the relationship and the CpG-ODN sequence with an optimum immunologic adjuvant effect is screened through internal and external tests. An adopted formula is as follows: the sequence of 10-100mug of CpG-ODN F3 of each chick is 5'-TCGTCGTTGTCGTTTTGTCGTTGGGGGG-3'. The local mucous membrane immunization and whole humoral immunization levels can be effectively improved under the cooperation with avian influenza inactivated virus through intranasal immunity, a muscle injection immunization process is avoided, the chicken stress reaction is reduced, and guarantee is provided for improving chicken quality. Moreover, the CpG-ODN cost is lowered, and the possibility of widely applying the artificial synthetic adjuvant to poultry vaccines is increased.
The invention relates to the technical field of medicinal preparations and discloses a dry cefdinir suspension and a preparation method thereof. The dry cefdinir suspension comprises cefdinir as an active component, a filling agent, a suspending aid, a disintegrating agent, a stabilizing agent, a flavoring agent, an aromatic and a flowing aid. The active component is micronized by a supercutical fluid technology so that particle sizes are less than 10 microns, a particle sedimentation rate is reduced and solubility is improved. The dry cefdinir suspension is prepared by a dry granulation technology so that a wet granulation process under wet-heat conditions which can produce influence on stability of cefdinir as an active component is avoided, the problem of poor fluidity of direct powder mixing is solved, and production efficiency is improved. The dry cefdinir suspension has a good taste, a fast oral absorption rate and high bioavailability. Through combination of the flavoring agent and the aromatic, compliance of patients is improved and especially, compliance of children is improved.
PROBLEM TO BE SOLVED: To enable the treatment of septic shock by the intravenous administration of an anti-tumor necrosis factor(TNF) monoclonal. antibody. SOLUTION: An aqueous solution of an anti-TNF monoclonal antibody is administered to a mammal by intravenous injection after the onset of septic shock at intervals of 30-60min at a rate of 1-10mg/kg body-weight. It can be applied to mammals including pig and man to alleviate the shock symptom and suppress the mortality. TNF-monoclonal antibody is produced by the culture of a hybridoma and purified by the separation of cell, precipitation with polyethylene glycol, anion-exchange treatment and sizeexclusion chromatography. An already established patient of shock symptom can be treated by a clinically effective method in contrast to the conventional method effective only for the prevention of shock.
Silymarin and green tea are the two most widely used botanical products used by patients with chronic hepatitis C virus (HCV) infection. A major limitation of prior clinical investigations that may account for lack of efficacy is their use of inadequate customary oral dose regimens. Ongoing Phase II studies utilizing higher than customary doses of silymarin are based on potential disease modifying effects resulting from the potent antioxidant properties of silymarin flavonolignans. Since patients often use more than one herbal product to self-treat their disease, the use of higher than customary doses of silymarin may change silymarin's potential for herbal-herbal interactions. Pharmacokinetic interactions between silymarin and green tea catechins may change their safety/tolerability profiles, and may increase their antioxidant effects through additive or synergistic pharmacodynamic interactions. The objective of this double blind, active placebo controlled, randomized clinical trial is to characterize the pharmacokinetics and to evaluate the safety, tolerability, and antioxidant effects of an herbal cocktail consisting of silymarin and epigallocatechin gallate (EGCG) standardized green tea extract in treatment-naïve patients with chronic HCV infection. This investigation will include two treatment arms that will enroll 15 subjects per arm. Subjects will be randomized to receive in a fixed sequence either: 1) 196.5 mg EGCG followed by the coadministration of 700 mg silymarin; or 2) 700 mg silymarin followed by the coadministration of 196.5 mg EGCG. Each dosing regimen will be administered p.o. every 12 hrs for 12 days. No treatment arm uses high doses for both silymarin and EGCG in a sequence. Depending on the treatment arm, pharmacokinetic studies will be performed on plasma concentrations for six major silymarin flavonolignans and for the green tea catechin, EGCG at the end of 12 days of either silymarin or green tea extract monotherapy (Period 1), and then again after 12 days of silymarin and green tea extract given in combination (Period 2). For each treatment arm, plasma 8F2α-isoprostane concentrations, a measure of oxidative stress, will also be determined at baseline, during each period, and then at follow-up. The results from this investigation will be used to identify doses of silymarin and green tea that can be used together safely for future efficacy trials in patients with different chronic liver diseases.
Fresh breast milk obtained from volunteer mothers will be divided into four parts. Fresh breast milk will be studied for microbiota composition immediately within 3 hours.
Focal segmental glomerular sclerosis (FSGS) is 1 of the primary causes of nephrotic syndrome in both pediatric and adult patients, which can lead to end-stage kidney disease. Recurrence of FSGS after kidney transplantation significantly increases allograft loss, leading to morbidity and mortality. Currently, there are no consensus guidelines for identifying those patients who are at risk for recurrence or for the management of recurrent FSGS. Our work group performed a literature search on PubMed/Medline, Embase, and Cochrane, and recommendations were proposed and graded for strength of evidence. Of the 614 initially identified studies, 221 were found suitable to formulate consensus guidelines for recurrent FSGS. These guidelines focus on the definition, epidemiology, risk factors, pathogenesis, and management of recurrent FSGS. We conclude that additional studies are required to strengthen the recommendations proposed in this review.
The invention discloses a colestyramine slow release capsule and a preparation method. The slow release capsule is prepared from the following components in parts by weight: 30-35 parts of colestyramine, 5-8 parts of slow release material, 15-20 parts of core pellet, 0.3-0.5 part of plasticizer and 0.5-0.8 part of pore-foaming agent. The preparation method comprises the following steps: material preparing, preparation of a colestyramine medicated pill core, preparation of a colestyramine slow release micropill, and capsulation. Lasting and slow drug release is realized in the body of the slow release capsule, blood concentration is stable, and fluctuation is little, thus reducing drug administration frequency and improving patient compliance. By controlling the concentrations of effective drug components in blood to maintain a drug effect, a number of drug release peak reaching times is reduced, and internal organs of a patient are protected to a certain extent. In a whole process, toxic organic reagents are not adopted, so going green and environmental protection are realized, and the stability is good.
Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
PURPOSE:To obtain an antibody having high antibody titer, specificity and affinity when peptide, protein and organic compound which have low antigenicity are used as immunogens by using basic protein as carrier protein. CONSTITUTION:Most of basic protein is bonded to nucleic acid such as DNA and RNA. The basic protein which is not present in body fluid in a large quantity is used as carrier protein. The basic protein is readily recognized as a foreign matter in a body. Immunological mechanism acts powerfully. The induction of an antibody for hapten containing the carrier protein is efficiently caused. Thus, the excellent antibody having the intended antibody titer, specificity and affinity can be efficiently obtained.
The invention relates to veterinary science. An extrarenal blood purification procedure is performed to remove toxins from the blood. Baseline parameters of urea and creatinine in the blood serum are measured during the blood purification procedure; on the basis of the data obtained, a dialysis intensity index (DII) is determined as the ratio of the patient's total fluid volume to the volume of the fluid purified of toxins and a uremic toxin accumulation index (UTAI) is determined as the rate of accumulation of the quantity of urea or creatinine per unit of time. Moreover, it is deemed necessary to repeat the haemodialysis procedure if the UTAI value for urea is more than 0.5 and/or the UTAI value for creatinine is more than 8, and/or the DII value is less than 0.9. In particular, in order to prevent thrombosis, an anticoagulant, dalteparin sodium, is administered to the animal by i/v infusion at a dosage of 35 IU/kg body weight followed by an i/v drip injection at a rate of 15 IU/kg/h. The method allows the UTAI values for urea and creatinine to be determined in each inter-dialysis period, changes in filtration ability of the kidneys to be observed, and a prediction to be made of whether or not repeat haemodialysis is required; the use of said procedure significantly increases the life expectancy of the animal.
BACKGROUND: As the prevalence of gastric cancer rises in aging populations, managing surgical risks and comorbidities in elderly patients presents a unique challenge. The Comprehensive Preoperative Assessment and Support (CPAS) program, through comprehensive preoperative assessments, aims to mitigate surgical stress and improve outcomes by enhancing patient awareness and preparation. This study investigates the efficacy of a CPAS program, incorporating frailty and sarcopenia evaluations, to improve short-term outcomes in elderly gastric cancer patients.
METHODS: A retrospective analysis was conducted on 127 patients aged 75 or older who underwent surgery with CPAS between 2018 and August 2023, compared to 170 historical controls from 2012 to 2017. Propensity score matching balanced both groups based on age-adjusted Charlson Comorbidity Index and surgical details. The primary focus was on the impact of CPAS elements such as rehabilitation, nutrition, psychological support, oral frailty, and social support on short-term surgical outcomes.
RESULTS: Among 83 matched pairs, the CPAS group, despite 40.4% of patients in the CPAS group and 21.2% in the control group had an ASA-PS score of 3 or higher (P < 0.001), demonstrated significantly reduced blood loss (100 ml vs. 190 ml, P = 0.026) and lower incidence of serious complications (19.3% vs. 33.7%, P = 0.034), especially in infections and respiratory issues. Sarcopenia was identified in 38.6% of CPAS patients who received tailored support. Additionally, the median postoperative hospital stay was notably shorter in the CPAS group (10 days vs. 15 days, P < 0.001), with no in-hospital deaths. These results suggest that personalized preoperative care effectively mitigates operative stress and postoperative complications.
CONCLUSION: Implementing CPAS significantly enhances surgical safety and reduces complication rates in elderly gastric cancer patients, emphasizing the critical role of personalized preoperative care in surgical oncology for this demographic.
PROBLEM TO BE SOLVED: To obtain a high calorie infusion containing glutamine. SOLUTION: An infusion containing 0.5-10 mass % glutamic acid is produced by using 1-500mmol/l L-lactic acid. The glutamine-containing infusion is preferably used in an amount of about (1/3) of total amino acid in a high calorie infusion agent. A lactic acid solution and dried glutamine are respectively stored in sealed plastic vessels, communicated through an injection needle in the use, a solvent of the lactic acid solution is mixed with the glutamine to dissolve the glutamine. Therefore, preferably a kit product is constructed by providing two cells composed of a cell sealing the glutamine powder and a cell sealing the solvent and divided by only a partition wall. In this case, a communication between both cells is performed by using an injection needle or by breaking the cell under a pressure by a hand.  As the glutamine is kept in a dried state until just before the use, stability of the glutamine in the infusion is surely preserved and preparing control of the infusion is simple. For a patient requiring complete vein nutrition, immunocompetence is increased and a recovering period can be shortened.
The multimodal treatment consists of 6 treatment sessions that will combine basic physiotherapy exercises to address dizziness and balance problems, training in deep breathing, progressive muscle relaxation, visualization to address headache, sleep hygiene education to address insomnia, and cognitive-behavioral intervention and gratitude exercises to promote coping and resilience. The treatment is designed to be implemented by a variety of clinical health care professionals.
Slow and controlled breathing exercises will be performed starting with 5 seconds of inhalation and 5 seconds of exhalation twice a day for 10 minutes, 5 days a week for eight weeks, with a 10-second diaphragmatic breathing cycle (6 breaths/minute). The finger counting method will be recommended so that participants can easily follow the 5-second inhalation and 5-second exhalation cycles. The exercises can be done sitting or lying down. The individuals will be taught the differences between the two by switching between normal and deep breathing a few times. The respiratory exercises will be finished with relaxation exercises.
The present invention is adapted for recognition technology improvement, which provides a memory identification and recovery method based on recognition, including: S1. collecting the data information from the scene of activity through a recognition device; S2. conducting salient feature extraction to the data information collected from the scene and generating feature marks; S3. building mapping relations between the generated feature marks and the extracted data information, automatically generating memory information in the database, and storing the information in the database; S4. inputting related data information for searching; S5. selecting a corresponding method to search the generated memory information in the database based on the input data information; S6. determining if there is related data information in the memory data. The method can helps to enhance memory of the user, recover memory after forget it, recover effectively through recognition technology, improve memory, and retrieve memory quickly after memory loss, which is convenient and efficient.
Improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA’s) or Cell Penetrating Peptides (CPP’s) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP’s (StaP’s) or ii) stitching three or more amino acids to form stitched CPP’s (StiP’s) are claimed. Said CPP’s are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM’s). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamate morpholino oligonucleotide (PMO). Said methods can be used the treatment of diseases a or genetic conditions. .
Purified whole ox-eyes are washed with 1/10000 methiolated water, subjected to autolysis at 0-4 degrees C for 4 days, washed and milled, stirred with twice the volume of ethanol and left for 24 hrs. The liquid is then expressed, filtered several times, carefully concentrated to dry, using 10% filter-aid in the last stage. After testing on residual protein, the residue is repeatedly taken up in water and centrifuged until the filter-aid is fully separated, and finally adjusted to the desired content of active principles. The product is a stimulant for biological functions in the organisms and strengthes the resistance against pathological agents, and contributes to the healing of eye-diseases. It may be used in ophthalmological therapy in cases of e.g. myopic chorio-retinitis, weak eyesight in all its forms, opacity of the vitreous body, iritis and irido-cyclitis, corneal ulceration etc. The extract may be used in ampoules as subconjunctive sprays or subcutaneously and also in eyedrops, compresses or eyebaths.
<P>PROBLEM TO BE SOLVED: To provide a cardiomyocyte differentiation inducing promoter and a method for using the same.  <P>SOLUTION: The cardiomyocyte differentiation inducing promoter includes IL-10 or progesterone as an active ingredient and promotes differentiation induction of mesenchymal stem cells to cardiomyocytes. The method for promoting cardiomyocyte differentiation includes treating mesenchymal stem cells in the presence of IL-10 or progesterone. The mesenchymal stem cells are cells having ability of differentiation to cardiomyocytes. The method for differentiation induction of mesenchymal stem cells to cardiomyocytes includes a step for culturing mesenchymal stem cells treated in the presence of IL-10 or progesterone on a feeder cell.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A clinical information management system. The clinical information management system is implemented by allocating  310  resources and conducting 320 medical procedures. The data from allocating the resources and conducting medical procedures is collected  330  in a database. After the completion of each medical procedure, work and cost reduction opportunities are identified  340  to establish  350  a benchmark for the average utilization of resources for a particular type of procedure once a benchmark is established, particular types of procedures may be standardized  360  to include only the necessary resources which are then requisitioned  370  for future procedures. Data is collected and stored for a clinical procedure. Waste and cost reduction opportunities are identified; resulting in the establishment of a benchmark. The clinical procedure is then standardized based upon the benchmark. Resources are requisitioned based upon the standardized procedure.
<P>PROBLEM TO BE SOLVED: To provide a hepatoprotectant composition with a strong hepatoprotective effect and to provide an easily administered hepatoprotectant composition.  <P>SOLUTION: The invention provides the hepatoprotectant composition comprising black cohosh plants body or its extracts as the active ingredient. The invention provides hepatoprotectant foods comprising black cohosh plants body or its extracts as an active ingredient. The invention provides foods and beverages comprising 0.3-200 mg (dry weight) of the black cohosh plants body or its extracts per 1g of the foods and beverages. The invention provides the method for using the black cohosh plants for preparation of the hepatoprotective composition or health supplemental foods for protection of hepatic function.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable of inhibiting the activity of sebaceous glands, preventing the occurrence of inflammations in the sebaceous glands and treating common acne without forming a common acne trace by including an extract from a plant of the genus Silybum of the family Compositae. SOLUTION: This cosmetic is obtained by including an extract of a plant of the genus Silybum of the family Compositae, e.g. Silybum marianum called Maria-azami, O-azami or Ohire-azami in an amount of preferably 0.0001-10.0 wt.% expressed in terms of a dried substance. In the above extract, silymarin, silybin, silychristin and silydianin, or the like, as active substances are present alone or as a mixture. The extraction from the whole herb of the plant or an individualized material such as leaf, a stem or a fruit is preferably carried out with an organic solvent having an intermediate polarity such as a lower alcohol, a lower polyhydric alcohol, e.g. propylene glycol or acetone or a mixed liquid thereof as a method for extraction.
INTRODUCTION: Surgeons are at high risk of developing musculoskeletal symptoms due to a range of factors including, maladaptive positioning and surgical ergonomics. Cervical muscle strain and biomechanical load is most prevalent due to repetitive motions and prolonged static neck positioning. This issue is apparent through reports of prevalence between 10 and 74.4% among surgeons. The aim of this systematic review is to provide an objective assessment of the clinical evidence available and a descriptive analysis of the effects of kinematics and surgical ergonomics on the prevalence of surgeons' cervical musculoskeletal pain.
METHODS: This is PRISMA-compliant systematic review of clinical studies assessing the prevalence of cervical musculoskeletal dysfunction in surgeons by searching PUBMED and Ovid EMBASE databases from inception to 19th October 2023. Study quality was graded according to the National Institutes of Health study quality assessment tools.
RESULTS: A total of 9 studies were included in the final qualitative analysis. The use of loupes, open surgery and excessive neck flexion (>30°) were associated with cervical dysfunction. Comparison of study outcomes was challenging due to heterogeneity within study methods and the paucity of methodological quality.
CONCLUSION: The current literature assessing ergonomic and biomechanical factors predisposing surgeons to cervical musculoskeletal dysfunction is insufficient to provide reliable guidance for clinicians. Although the literature identifies factors contributing to work-related cervical dysfunction, few attempt to evaluate interventions for improved surgical ergonomics. An objective assessment of interventions that prompt postural correction with the aim to improve neck pain in surgeon cohorts is warranted.
For psoriasis, apply a thin layer of VANOS Cream once or twice daily to the affected skin areas as directed by a physician. Twice daily application for the treatment of psoriasis has been shown to be more effective in achieving treatment success during 2 weeks of treatment.

For atopic dermatitis, apply a thin layer of VANOS Cream once daily to the affected skin areas as directed by a physician. Once daily application for the treatment of atopic dermatitis has been shown to be as effective as twice daily treatment in achieving treatment success during 2 weeks of treatment (See CLINICAL STUDIES).

For corticosteroid responsive dermatoses, other than psoriasis or atopic dermatitis, apply a thin layer of VANOS Cream once or twice daily to the affected areas as directed by a physician.

Treatment with VANOS Cream should be limited to 2 consecutive weeks, and no more than 60 g/week should be used. Do not use more than half of the 120 g tube per week.

Therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.